𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma

✍ Scribed by Walter M. Stadler; Apurva A. Desai; David I. Quinn; Ronald Bukowski; Bernard Poiesz; Carl G. Kardinal; Nancy Lewis; Alex Makalinao; Peter Murray; Frank M. Torti

Publisher
Springer
Year
2007
Tongue
English
Weight
266 KB
Volume
61
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch